About Laurus Labs Ltd
Laurus Labs offers a broad and integrated portfolio of Active Pharma Ingredients (API) including intermediates, Generic Finished Dosage Forms (FDF) and Contract Research services to cater to the needs of the global pharmaceutical industry.
Founded
2005
CEO
Ravindranath Kancherla
Employees
13,832
HQ
Hyderabad, India
Finished Products
1API & Drug Intermediate
₹29,476.31Cr2Sale of Traded Goods
₹839.40Cr3Contract Research Income
₹775.47Cr4Other Operating Revenue
₹174.23Cr5Scrap Sales
₹70.19Cr6Export and other incentives
₹32.05CrRaw Materials
1Raw Materials consumed
₹7,137.16Cr2Purchase of Traded Goods
₹2,873.71Cr3Packing Materials
₹2,870.06CrAbout Laurus Labs Ltd
Laurus Labs offers a broad and integrated portfolio of Active Pharma Ingredients (API) including intermediates, Generic Finished Dosage Forms (FDF) and Contract Research services to cater to the needs of the global pharmaceutical industry.
Founded:2005
CEO:Ravindranath Kancherla
Employees:13,832
HQ:Hyderabad, India
Finished Products
1API & Drug Intermediate
₹29,476.31Cr2Sale of Traded Goods
₹839.40Cr3Contract Research Income
₹775.47Cr4Other Operating Revenue
₹174.23Cr5Scrap Sales
₹70.19Cr6Export and other incentives
₹32.05CrRaw Materials
1Raw Materials consumed
₹7,137.16Cr2Purchase of Traded Goods
₹2,873.71Cr3Packing Materials
₹2,870.06CrPrice Performance & Market EventsPrice Performance
Loading chart data…
Key Metrics
Trading & valuation snapshot
52W High
₹1,949
52W Low
₹823
Volume2.27M
Avg VolumeN/A
Beta0.87
Dividend Yield0.11%
Key Financial Ratios
Profitability, leverage & efficiency at a glance
P/E Ratio
92.17x
Valuation
P/B Ratio
18.96x
Valuation
EPS
₹20.18
Valuation
Dividend Yield
0.11%
Valuation
ROE
16.77%
Profitability
ROCE
16.14%
Profitability
Revenue by Segment
Contribution & growth by business line
PharmaceuticalsRevenue split N/A
Geographical Revenue Split
Domestic vs international exposure
Domestic
32.9%
International
67.1%
Outside India67.1%
Within India32.9%
Strategic Relations
Collaborations, joint ventures & subsidiaries
No collaborations data available.
Forensic Metrics
Financial health & earnings-quality indicators
Revenue Quality
N/A
Days Sales Outstanding
Leverage
0.48x
Debt-to-Equity
Earnings Quality
N/A
Cash Conversion Ratio
Efficiency
N/A
Asset Turnover
Earnings Quality
N/A
Accruals Ratio
Profitability
N/A
Gross Margin
Growth
10.6%
Sales Growth
These metrics are derived from available financial disclosures and market data. Use them together with company filings and qualitative analysis before making decisions.